www.nature.com/nrcardio
NEWS & VIEWS
The primary efficacy end point of the study-the rate of HF-related hospitalizations at 6 months-was reduced by 30% (hazard ratio [HR] 0.70, 95% CI 0.60-0.84, P <0.0001). During the entire 15 months of follow-up, the CardioMEMS ® group had a 39% reduction in HF-related hospitalizations, without a concomitant increase in non-HF-related hospitalizations. This group also had significant reductions in pulmonary artery mean pressure and the number of patients admitted to hospital, a significant increase in the number of days patients spent alive outside hospital, and significant improvements in quality of life compared with the control group. The number needed to treat with the CardioMEMS ® device to prevent one HF-related hospitalization and the incremental cost-effectiveness ratio were also both favorable. Notably, the benefits of sensor-guided treatment were similar in patients with preserved LVEF and in those with reduced LVEF, making this system one of the few management approaches ever demonstrated to improve outcomes in patients with HF and preserved LVEF. The sensor was fairly safe, and freedom from device-related or system-related complications was 98.6%. Furthermore, no sensor failures occurred during follow-up. 8 This trial nicely demonstrates clinically relevant reductions in HF-related hospitalizations in patients with moderately severe HF when managed with the wireless implantable hemodynamic monitoring system.
Given the considerable, and largely unmitigated, burden of HF, the potential of these implantable hemodynamic monitoring devices to revolutionize the management of patients with HF is substantial. However, it should be noted that this study was not powered to detect differences in mortality, and whether survival can be improved with this enhanced hemodynamic monitoring system remains unknown. Importantly, as the device was tested in a select cohort of patients being followed up at experienced centers, additional study will be needed to determine whether these findings can be generalized to a broader cohort of patients and a more-diverse group of clinicians and clinical practice settings. Further investigation is also needed to determine the safety and efficacy of providing data from the hemodynamic sensors directly to patients, so that these devices can be employed for self-management of HF.
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Inflammation has a pivotal role in cardiac remodeling, and circulating biomarkers of inflammation are independently associated with risk of developing heart failure and with prognosis after onset of the condition. Pentraxin 3 has been suggested as a novel biomarker of left ventricular diastolic dysfunction and heart failure with normal ejection fraction. A major strength of the study is the fact that the investigators demon strated that pentraxin 3 is produced in the coronary circulation, which supports the existence of a myo cardial source for this biomarker and strengthens the evidence for the role of this protein in cardiac remodel ing. 10 However, since experi mental data suggest that pentraxin 3 decreases vascular inflammation and athero sclerosis, 8 this marker is more likely to actually modulate, rather than promote, myocardial remodeling processes.
In conclusion, the clinical application of assessing blood pentraxin-3 levels remains unclear at present. The data by Matsubara and colleagues 5 indicate that circulating pentraxin 3 is not useful for distinguishing HFPEF from HFREF, but that it correlates with LV diastolic dysfunction (or with elevated LV filling pressures). However, we still do not know whether pentraxin-3 levels can predict the development of HF, help in its clinical diagnosis (when diagnostic uncertainty exists), or carry any prognostic information in the setting of overt HF. How pentraxin 3 would compare with established HF biomarkers, such as the B-type natriuretic peptide, for these different clinical purposes is also not clear. Additional studies are warranted to address these issues. ...the elevation of pentraxin-3 levels ... was more pronounced than the elevation in blood levels of CRP...
''
interleukin (IL) 6 or tumor necrosis factor (TNF), independently predict future HF and prognosis in those with existing HF.
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However, which markers of inflammation, if any, should be used to assess future risk of HF in indivi duals free of this condition, to facilitate diagnosis in patients with symptoms suggestive of HF, or to estimate prognosis in patients with overt HF is not clear. In addition, the pathophysiological role of many bio markers (including inflammatory markers) in HF is poorly understood, that is, whether a given marker is causally involved in cardiac remodeling, whether it is upregulated in a compensatory manner, or whether it is simply an epiphenomenon of a catabolic state caused by HF is not clear. Furthermore, we do not know whether the increase in circu lating levels of many of these bio markers in the setting of HF reflects increased local cardiac synthesis per se, or whether it just reflects a systemic inflammatory state. In this context, Matsubara and colleagues evaluated the relationship between circulating levels of pentraxin 3, a novel marker of inflammation, and the presence of diastolic dysfunction and/or overt HF. 5 Pentraxins are members of a superfamily of multimeric pattern-recognition proteins that have a characteristic molecular ring structure consisting of five monomers and that can be short (such as CRP and serum amyloid associated protein, which are typically produced by the liver) or long (the prototype of this group being pentraxin 3). These proteins are evolutionarily highly conserved and have important roles at the interface of innate immune response, inflammation, and extracellular matrix remodeling. 6 Pentraxin-3 knockout mice are highly susceptible to fungal infections, 7 and double pentraxin-3 and apolipoprotein-E knockout mice are also more prone to developing athero sclerosis than single apolipoprotein-E knockout animals. 8 In contrast to CRP, which is mainly produced by the liver in response to stimulation by IL-6, pentraxin 3 is produced by a variety of cell types (mainly myeloid dendritic cells, but also mono nuclear cells, neutro phils, smooth muscle cells, adipocytes, fibroblasts, and others). 9 The expression of pentraxin 3 is stimulated by various inflammatory molec ular cascades, in particular toll-like receptor signaling. 9 In their study, Matsubara and colleagues analyzed circulating levels of pentraxin 3 in a sample of 171 individuals without HF, 82 individuals with HFPEF, and 70 individuals with HFREF. 5 The investigators report that, in individuals without HF, circulating pentraxin 3-but not circulating CRP, IL-6 or TNF-was associated with the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (E/E' ratio), a quantitative echocardiographic measure of LV diastolic dysfunction. In addition, circulating pentraxin-3 levels were higher in the group with HFPEF than in individuals without HF. Again, the elevation of pentraxin-3 levels in patients with HFPEF was more pronounced than the elevation in blood levels of CRP, IL-6 or TNF. However, patients with HFREF had even higher circulating pentraxin-3 levels than those with HFPEF. Lastly, the investigators measured higher levels of pentraxin 3 in the coronary sinus than in the aortic root in individuals with diastolic dysfunction but no HF, in those with HFPEF, and in those with HFREF, demonstrating that pentraxin 3 is produced in the coronary circulation in these conditions. Matsubara et al. conclude that pentraxin 3 is an independent marker of LV diastolic dysfunction and of HFPEF, and that the myocardium is likely to contribute to the increase in circulating levels of this protein.
Several aspects are involved in the appraisal of this study. First, the reported relationship between pentraxin 3 and LV diastolic dysfunction is a purely statistical association in an observational study. Limited data exist regarding the clinical, biochemical, and echocardiographical correlates of circulating pentraxin 3. Hence, potential confounders of the association between pentraxin 3 and LV diastolic function remain to be identified. Second, the observation that blood pentraxin-3 levels in patients with HFREF were even higher than those in patients with HFPEF is not easy to interpret. Although LV diastolic dysfunction, which characterizes HFPEF, is also common in patients with HFREF, the concept that pentraxin 3 is primarily a marker of LV diastolic dysfunction is questionable. Indeed, raised pentraxin-3 levels in the setting of HF might simply represent elevated LV filling pressures or increased wall tension. Third, the statistical power of the study to evaluate pentraxin 3 as a screening biomarker of
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has proven to be remarkably free of adverse effects. 4 Solomon and colleagues, therefore, designed the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) 5 to determine whether the addition of the FDA-approved renin inhibitor aliskiren to background hormone-inhibiting therapy would further attenuate the left ventricular remodeling process.
Echocardiography was used to quantify changes in left ventricular structure and function over a 9-month follow-up period in the placebo and aliskiren groups. More than 300 patients in each treatment arm had measurements that could be evaluated at baseline and end point. No differences in left ven tricular effects between the two treatment arms could be detected by imaging. The apparently negative results of this study suggest that renin inhibition added to standard therapy does not produce further attenuation of left ventricular remodeling
